Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
1.
Acta Oncol ; 53(1): 80-7, 2014 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-24059270

RESUMO

BACKGROUND: Alopecia is a frequently occurring side effect of chemotherapy that often can be prevented by cooling the scalp during the infusion. This study compared effects and costs of scalp cooling with usual general oncological care, i.e. purchasing a wig or head cover. MATERIAL AND METHODS: Scalp-cooled patients (n = 160) were compared with non-scalp-cooled patients (n = 86) at 15 Dutch hospitals. Patients were enrolled prior to anthracycline and/or taxane-based chemotherapy for several types of cancer between 2007 and 2008. Cost-effectiveness of scalp cooling compared with that of usual care was determined by the ratio of costs to quality adjusted life years (QALYs). Costs for scalp cooling (machines and nursing time), hair dressers, wigs and head covers were estimated from a societal perspective. QALYs were measured using the Short Form-36. RESULTS: Scalp cooling reduced the use of a wig or head cover by 40%, but wigs were still purchased unnecessarily by 38% of scalp-cooled patients. Average societal costs decreased therefore only by €269 per patient due to scalp cooling (p = 0.02). Given the eligibility for scalp cooling at the time, the insignificant difference in QALYs resulted from a balance of the benefits for those patients with successful scalp cooling and those without success. For the Dutch, given the generally accepted threshold of willingness to pay for a QALY (between €20 000 and €40 000), scalp cooling was cost-effective, therefore justifying the choice of scalp cooling or purchasing a wig or head cover. CONCLUSION: Given the right indication, cost-effectiveness might be improved further by postponing wig and head cover purchases, by improving scalp cooling efficacy, as well as using the scalp cooling capacity more intensively.


Assuntos
Alopecia/economia , Alopecia/prevenção & controle , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Hipotermia Induzida/economia , Neoplasias/tratamento farmacológico , Couro Cabeludo , Adulto , Idoso , Alopecia/induzido quimicamente , Estudos de Casos e Controles , Análise Custo-Benefício , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Neoplasias/complicações , Neoplasias/economia , Prognóstico , Estudos Prospectivos , Qualidade de Vida , Anos de Vida Ajustados por Qualidade de Vida
2.
Curr Opin Oncol ; 23(2): 189-96, 2011 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-21192263

RESUMO

PURPOSE OF REVIEW: Epidemiological data have contributed to the classification in 2009 of the full ultraviolet (UV) radiation spectrum as carcinogenic to humans. We reviewed the epidemiological evidence that UVA could be involved in the genesis of cutaneous melanoma. RECENT FINDINGS: Use of artificial UV tanning devices (sunbeds) consists mainly of repeated exposure to high UVA doses. Epidemiological studies published over the last years confirmed the association between sunbed use and melanoma. Sunbed use is the most probable cause of an epidemic of melanoma that took place in Iceland from 1990 to 2006. The four-fold increase in melanoma incidence was not followed by an increase in melanoma mortality. Sunscreens were primarily devised for the prevention of sunburn, and UVB is the wavelength causing most sunburns. All observational studies and randomized trials show that sunscreen use may extend sun exposure intended for getting a tan, while it does not necessarily decrease sunburn occurrence. Sunscreen use for tan acquisition would thus lead to similar exposure to UVB and greater exposure to UVA, which could explain the slightly higher melanoma risk often found among sunscreen users. SUMMARY: UVA could be involved in the occurrence of nonlife-threatening melanoma. The increasing use of sunbeds and of sunscreens may partly explain why melanoma incidence increases in most light-skinned populations without concomitant increase in mortality.


Assuntos
Melanoma/epidemiologia , Lesões por Radiação/epidemiologia , Neoplasias Cutâneas/epidemiologia , Raios Ultravioleta/efeitos adversos , Humanos , Melanoma/etiologia , Lesões por Radiação/etiologia , Neoplasias Cutâneas/etiologia
3.
Eur J Cancer ; 157: 81-93, 2021 11.
Artigo em Inglês | MEDLINE | ID: mdl-34492587

RESUMO

BACKGROUND: This is the first national study on trends in cancer survival and mortality for children and young adolescents in the Netherlands including unique information on stage at diagnosis. METHODS: All neoplasms in patients <18 years, diagnosed between 1990 and 2015 (N = 14,060), were derived from the Netherlands Cancer Registry. Cohort and period survival analyses were used to estimate observed survival (OS). Time trends in OS and mortality rates were evaluated by parametric survival models and average annual percentage change, respectively. RESULTS: Between 1990 and 2015, 5-year OS and 10-year OS of childhood and young adolescent cancer have improved significantly by 9 percent points, reaching 81% and 78%, respectively. Favourable trends in survival were observed for all age groups and most diagnostic (sub)groups, being particularly pronounced for advanced disease. Non-Hodgkin lymphomas Ann Arbor stage III, metastatic neuroblastomas (age ≥18 months) and Ewing bone sarcomas showed significant improvements in 5-year OS. Compared with 1990-99, the risk of dying within five years of diagnosis was decreased significantly during 2000-09 (hazard ratio [HR] = 0.8) and 2010-15 (HR = 0.6), after adjustment for age, gender and follow-up time. Nonetheless, the prognosis of young patients suffering from central nervous system tumours, neuroblastoma and osteosarcomas remained modest, with 5-year OS <70% and 10-year OS <65%. Childhood and young adolescent cancer mortality decreased by an average of 2.0% annually between 1990 and 2018. CONCLUSIONS: Significant progress has been realised in the prognosis of childhood and young adolescent cancer in the Netherlands since the 1990s. Survival improvements were especially evident for patients with advanced stages and were also reflected in the declining mortality rates.


Assuntos
Neoplasias/mortalidade , Adolescente , Neoplasias Ósseas/mortalidade , Neoplasias do Sistema Nervoso Central/mortalidade , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Recém-Nascido , Masculino , Estadiamento de Neoplasias , Neoplasias Embrionárias de Células Germinativas/mortalidade , Países Baixos/epidemiologia , Sarcoma/mortalidade
4.
Acta Oncol ; 49(8): 1227-34, 2010 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-20583946

RESUMO

BACKGROUND: The availability of quality assured, population-based cancer registries and biobanks with high quality samples makes it possible to conduct research on large samples sets with long follow-up within a reasonable time frame. Defined quality for both cancer registries and biobanks is essential for enabling high quality biobank-based research. Recent networking projects have brought these infrastructures together to promote the combined use of cancer registries and biobanks in cancer research. MATERIALS AND METHODS: In this report we review the current status and future perspectives of cancer registries and biobanks and how the interface between them should be developed to optimally further cancer research. RESULTS AND DISCUSSION: Major conclusions for future improvements are that the research exploiting cancer registries and biobanks, and the research that is building and optimising the infrastructure, should evolve together for maximally relevant progress. Population-based and sustainable biobanks that continuously and consecutively store all samples ("Biological registries") under strict quality control are needed. There is also a need for increased education, information and visibility of the interdisciplinary sciences required for optimal exploitation of these resources.


Assuntos
Pesquisa Biomédica , Neoplasias , Sistema de Registros , Bancos de Tecidos , Congressos como Assunto , Guias como Assunto , Humanos , Política Pública/tendências , Sistema de Registros/normas , Bancos de Tecidos/ética , Bancos de Tecidos/normas , Bancos de Tecidos/tendências
5.
Breast Cancer Res Treat ; 118(2): 425-32, 2009 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-19238536

RESUMO

Breast cancer is the most common female cancer in Europe, but its incidence and mortality are rapidly changing across Europe. The early termination of the women's health initiative (WHI) trial, after the detection of an increased breast cancer risk in hormone replacement therapy (HRT) users, was followed by strong declines of HRT use worldwide. We investigated whether the reduction of HRT sales affected breast cancer incidence in the Belgian province Limburg. All women registered in the Limburg Cancer Registry with a diagnosis of invasive breast cancer diagnosed between 1/1/1996 and 31/12/2005 were included in the study. Data on the use of HRT in the population were obtained from the vendors and the social security system. For age-standardization using the direct method, the European standard population was taken. In 2003 and 2004, the breast cancer incidence rate decreased significantly as compared to 2002 for women aged between 50 and 69 years. This sudden drop in the incidence intercepted a markedly increasing trend until 2002, but was followed again by an increase in 2005. Between 2002 and 2006, the sales of HRT (about 75% to women aged 50-69 years) were reduced by 41%. Breast cancer incidence was maximally related to HRT use in the previous year (R(2) = 77%). The decrease of breast cancer incidence in the Belgian province of Limburg may largely be related to the fall of HRT use following the early termination of the WHI trial. This suggests that HRT stimulates the growth of pre-existing, clinically latent tumours that may not otherwise become clinically apparent.


Assuntos
Neoplasias da Mama/epidemiologia , Terapia de Reposição de Estrogênios/efeitos adversos , Adulto , Distribuição por Idade , Idoso , Bélgica/epidemiologia , Feminino , Humanos , Incidência , Pessoa de Meia-Idade , Sistema de Registros
6.
Int J Cancer ; 122(9): 2106-14, 2008 May 01.
Artigo em Inglês | MEDLINE | ID: mdl-18183593

RESUMO

Incidence of cancer may vary within a country and over time because of previous differences in exposure to risk factors or interventions for early detection (screening). This study describes time-space trends of incidence of common cancer sites across the Netherlands during the period 1989-2003 and speculates on the reasons for the observations. From the Netherlands Cancer Registry, World standardized incidence rates per municipality were smoothed calculating weighted averages for each 2 km by 2 km grid of the population mid-points of neighbouring municipalities and presented as map animations. Spatial relative changes in incidence were estimated by comparing the periods 1989-1994 and 1998-2003. Complete time-space trends can be found as map animations on http://maps.ikcnet.nl. The incidence of cervical and stomach cancer (for both sexes) decreased, being higher in the cities than in the rural areas during all periods and contrasting the trends in colorectal and breast cancer. The relative increase in incidence of lung cancer among females was highest in the rural north, but the incidence remained higher in the cities of the mid-west Netherlands. For males, there was a marked decrease in lung cancer incidence across the country since 1991. Incidence of melanoma increased, rates being twice as high in the coastal area than in the cities. Prostate cancer maps largely replicated the known history of PSA-testing in the Netherlands. Time-space cancer incidence patterns gave insight into effects of changes in exposure to risk determinants and early detection. The maps illustrate marked potential for cancer prevention at the national and regional level.


Assuntos
Neoplasias/epidemiologia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Criança , Pré-Escolar , Diagnóstico Precoce , Feminino , Neoplasias Gastrointestinais/epidemiologia , Humanos , Incidência , Neoplasias Pulmonares/epidemiologia , Masculino , Programas de Rastreamento , Melanoma/epidemiologia , Pessoa de Meia-Idade , Neoplasias/diagnóstico , Neoplasias/etiologia , Neoplasias/prevenção & controle , Países Baixos/epidemiologia , Sistema de Registros , Estudos Retrospectivos , Fatores de Risco , Neoplasias Cutâneas/epidemiologia , Neoplasias Urogenitais/epidemiologia
8.
J Clin Epidemiol ; 57(9): 973-7, 2004 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-15504640

RESUMO

BACKGROUND AND OBJECTIVE: In many observational studies, the association between drugs and disease is analyzed with information from a baseline interview. We investigated the magnitude and direction of exposure misclassification by comparing interview data at baseline with prospectively gathered pharmacy data. METHODS: The study population for this study consisted of a cohort of 2,487 participants aged 71 years or older from the Rotterdam Study. Data on drug use were gathered at the baseline interview and through pharmacies during the follow-up period between January 1, 1991, and January 1, 1999. We assessed the sensitivity, specificity, and positive and negative predictive value of interview data as proxy measures of chronic use of calcium channel blockers (CCB) in comparison with longitudinal medication records from the pharmacy. RESULTS: Only 3 of the 206 subjects (1.5%) who reported use at baseline did not use CCBs during follow-up. Of the 2,281 persons who reported no use of CCBs at baseline, however, 354 actually used CCBs during follow-up (15.5%). The difference between interview data and pharmacy records corresponded to a misclassification bias of 0.73 (95%CI: 0.52-1.02). CONCLUSION: Misclassification of exposure was high when interview data were used as a proxy measure of chronic use during follow-up.


Assuntos
Bloqueadores dos Canais de Cálcio/administração & dosagem , Neoplasias/induzido quimicamente , Idoso , Idoso de 80 Anos ou mais , Viés , Bloqueadores dos Canais de Cálcio/efeitos adversos , Relação Dose-Resposta a Droga , Esquema de Medicação , Prescrições de Medicamentos/estatística & dados numéricos , Métodos Epidemiológicos , Feminino , Humanos , Masculino , Prontuários Médicos/estatística & dados numéricos , Neoplasias/epidemiologia , Países Baixos/epidemiologia , Farmácias/estatística & dados numéricos , Farmacoepidemiologia/métodos
9.
Eur J Cancer ; 49(7): 1683-91, 2013 May.
Artigo em Inglês | MEDLINE | ID: mdl-23265703

RESUMO

INTRODUCTION: Cancer registration coverage and cancer control programmes in South Eastern (SE) Europe, embracing about six new EU member states, remain thin, despite a relatively high incidence and mortality burden from avoidable cancers, particularly in males. We assembled the most recent cancer registry data to estimate the burden of the 17 most common cancers in the region, from Slovenia to Cyprus and Malta. METHODS: Data were made available for analysis from Bulgaria, Croatia, Cyprus, Malta, Romania (Cluj County), Serbia, Slovenia and Turkey (Antalya and Izmir provinces). We analysed incidence and mortality of the 17 most common cancers (counts and age-standardised rates, for the most recent year available and for the period 1999-2008). We used Joinpoint regression to quantify recent trends. FINDINGS: For much of SE Europe, there were no marked declines in overall cancer mortality rates during 1999-2008. In men, lung cancer incidence and mortality rates were high compared to other European countries (age-standardised rates (ASRW) of incidence being 50-60/100,000 in most of the countries), and still increasing in Bulgaria, Serbia and Turkey. Prostate cancer incidence rapidly increased throughout the region by 3-12% annually, largely without any clear declines in mortality. Colorectal cancer incidence increased throughout the region, as did mortality especially in Croatia, Serbia and Bulgaria (average annual percentage change (AAPC) 1.5-2%). In women, breast cancer mortality significantly declined in Slovenia, Croatia and Malta (Average Annual Percentage of Change [AAPC] -2%, -1% and -5%, respectively), but not elsewhere. Cervical cancer incidence rates remained very high in Romania, Serbia and Bulgaria (ASRW>20/100,000). INTERPRETATION: Our data confirmed the North West to South East Europe gradient of increasing incidence and mortality rates of tobacco-related cancers, as well as increasing mortality rates of screen-detectable cancers. The lack of decline in overall cancer mortality also indicates suboptimal levels of cancer control in the region.


Assuntos
Mortalidade/tendências , Neoplasias/mortalidade , Sistema de Registros/estatística & dados numéricos , Neoplasias da Mama/epidemiologia , Neoplasias da Mama/mortalidade , Neoplasias Colorretais/epidemiologia , Neoplasias Colorretais/mortalidade , Europa (Continente)/epidemiologia , Europa Oriental/epidemiologia , Feminino , Humanos , Incidência , Neoplasias Pulmonares/epidemiologia , Neoplasias Pulmonares/mortalidade , Masculino , Neoplasias/epidemiologia , Neoplasias da Próstata/epidemiologia , Neoplasias da Próstata/mortalidade , Análise de Regressão , Taxa de Sobrevida/tendências
10.
Lancet Oncol ; 8(9): 773-83, 2007 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-17714991

RESUMO

BACKGROUND: EUROCARE is the largest population-based cooperative study on survival of patients with cancer. The EUROCARE project aims to regularly monitor, analyse, and explain survival trends and between-country differences in survival. This report (EUROCARE-4) presents survival data for eight selected cancer sites and for all cancers combined, diagnosed in adult (aged >/=15 years) Europeans in 1995-99 and followed up until the end of 2003. METHODS: We analysed data from 83 cancer registries in 23 European countries on 2 699 086 adult cancer cases that were diagnosed in 1995-99 and followed up to December, 2003. We calculated country-specific and mean-weighted age-adjusted 5-year relative survival for eight major cancers. Additionally, case-mix-adjusted 5-year survival for all cancers combined was calculated by countries ranked by total national expenditure on health (TNEH). Changes to survival were analysed relative to cases diagnosed in 1990-94. FINDINGS: Mean age-adjusted 5-year relative survival for colorectal (53.8% [95% CI 53.3-54.1]), lung (12.3% [12.1-12.5]), breast (78.9% [78.6-79.2]), prostate (75.7% [75.2-76.2]), and ovarian (36.3% [35.7-37.0]) cancer was highest in Nordic countries (except Denmark) and central Europe, intermediate in southern Europe, lower in the UK and Ireland, and worst in eastern Europe. Survival for melanoma (81.6% [81.0-82.3]), cancer of the testis (94.2% [93.4-95.0]), and Hodgkin's disease (80.0% [79.0-81.0]) varied little with geography. All-cancer survival correlated with TNEH for most countries. Denmark and UK had lower all-cancer survival than countries with similar TNEH; Finland had high all-cancer survival, but moderate TNEH. Survival increased and intercountry survival differences narrowed between the data for 1990-94 and 1995-99 for, notably, Hodgkin's disease (range 66.1-82.9 [IQR 72.2-78.6] vs 74.0-83.9 [78.6-81.9]), colorectal (29.4-56.7 [45.8-54.1] vs 38.8-59.7 [50.7-57.5]), and breast (61.7-82.7 [72.3-78.3] vs 69.3-87.6 [76.6-82.7]) sites. INTERPRETATION: Increases in survival and decreases in geographic differences over time, which are mainly due to improvements in health-care services in countries with poor survival, might indicate better cancer care. Wealthy countries with high TNEH generally had good cancer outcomes, but those with conspicuously worse outcomes than those with similar TNEH might not be allocating health resources efficiently.


Assuntos
Inquéritos Epidemiológicos , Neoplasias/mortalidade , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Europa (Continente) , Custos de Cuidados de Saúde , Humanos , Pessoa de Meia-Idade , Sistema de Registros , Alocação de Recursos , Fatores Socioeconômicos , Análise de Sobrevida
11.
Int J Cancer ; 119(11): 2665-72, 2006 Dec 01.
Artigo em Inglês | MEDLINE | ID: mdl-16929492

RESUMO

This study investigates the difference in cancer mortality rates between migrant groups and the native Dutch population, and determines the extent of convergence of cancer mortality rates according to migrants' generation, age at migration and duration of residence. Data were obtained from the national cause of death and population registries in the period 1995-2000. We used Poisson regression to compare the cancer mortality rates of migrants originating from Turkey, Morocco, Surinam, Netherlands Antilles and Aruba to the rates for the native Dutch. All-cancer mortality among all migrant groups combined was significantly lower when compared to that of the native Dutch population (RR = 0.55, CI: 0.52-0.58). For a large number of cancers, migrants had more than 50% lower risk of death, while elevated risks were found for stomach and liver cancers. Mortality rates for all cancers combined were higher among second generation migrants, among those with younger age at migration, and those with longer duration of residence. This effect was particularly pronounced in lung cancer and colorectal cancer. For most cancers, mortality among second generation migrants remained lower compared to the native Dutch population. Surinamese migrants showed the most consistent pattern of convergence of cancer mortality. The generally low cancer mortality rates among migrants showed some degree of convergence but did not yet reach the levels of the native Dutch population. This convergence implies that current levels of cancer mortality among migrants will gradually increase in future years if no specific preventive measurements are taken.


Assuntos
Neoplasias/mortalidade , Migrantes , Adolescente , Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Neoplasias/classificação , Países Baixos/epidemiologia , Fatores de Risco
12.
Am J Epidemiol ; 157(6): 510-6, 2003 Mar 15.
Artigo em Inglês | MEDLINE | ID: mdl-12631540

RESUMO

Earlier epidemiologic studies have suggested an inverse association between non-Hodgkin's lymphoma and exposure to histamine(2) (H(2)) blockers, nonsteroidal anti-inflammatory drugs, cholesterol-lowering drugs, and antibiotics. Data from the PHARMO database were used to conduct a nested, population-based case-control study that included 1985-1998 drug-dispensing records for 300,000 residents of six Dutch cities. Included were those subjects without a previous history of cancer who were aged >/=20 years and were registered with an incident primary discharge diagnosis of non-Hodgkin's lymphoma between 1991 and 1998. This paper includes data on 211 cases and 800 controls individually matched on sex, age, community pharmacy, calendar time, and duration of follow-up. Conditional logistic regression analysis was used to evaluate the association between non-Hodgkin's lymphoma and categories of cumulative drug use in days. In multivariate analyses, nonsignificant risk reductions were found for all drugs tested, and the negative association tended to increase with increasing duration of use. For women, the odds ratio for H(2) blockers was 0.29 (95% confidence interval: 0.12, 0.69) and for analgesics was 0.40 (95% confidence interval: 0.22, 0.71). Results support an inverse association between occurrence of non-Hodgkin's lymphoma and use of H(2) blockers and analgesics among women, and they warrant confirmation in larger studies.


Assuntos
Anti-Inflamatórios não Esteroides/uso terapêutico , Antagonistas dos Receptores H2 da Histamina/uso terapêutico , Hipolipemiantes/uso terapêutico , Linfoma não Hodgkin/prevenção & controle , Adulto , Idoso , Idoso de 80 Anos ou mais , Estudos de Casos e Controles , Bases de Dados Factuais , Feminino , Humanos , Modelos Logísticos , Linfoma não Hodgkin/epidemiologia , Masculino , Registro Médico Coordenado/métodos , Pessoa de Meia-Idade , Países Baixos/epidemiologia , Farmacoepidemiologia
13.
Cancer Causes Control ; 14(7): 639-44, 2003 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-14575361

RESUMO

OBJECTIVE: Earlier studies with data on drug use from interview suggested that corticosteroids, estrogens and psychotropics may increase the risk of non-Hodgkin's lymphoma (NHL). The objective of this case-control study with complete pharmacy records was to investigate whether these results could be reproduced. METHODS: Cases were all subjects aged 20 years and older in a population of approximately 300,000 residents in the Netherlands who were registered with an incident primary discharge diagnosis of NHL between January 1, 1991 and December 31, 1998. Controls were matched to cases on sex, year of birth, community pharmacy, calendar period and total duration of medication history. Conditional logistic regression was used to evaluate the association between categories of cumulative drug use in days and the risk of NHL. RESULTS: 997 controls were matched to 251 cases of NHL that occurred during the study period. In multivariate analyses, there was no statistically significant risk increase of NHL after exposure to corticosteroids, estrogens or psychotropics. Moreover, long-term use of benzodiazepines showed an unexpected statistically significant protective effect (OR 0.34; 95% confidence interval 0.18-0.64). CONCLUSIONS: In our population-based study, corticosteroids, estrogens and psychotropics were not associated with an increased risk of NHL.


Assuntos
Corticosteroides/efeitos adversos , Estrogênios/efeitos adversos , Linfoma não Hodgkin/epidemiologia , Psicotrópicos/efeitos adversos , Adulto , Idoso , Idoso de 80 Anos ou mais , Estudos de Casos e Controles , Distribuição de Qui-Quadrado , Feminino , Humanos , Modelos Logísticos , Linfoma não Hodgkin/induzido quimicamente , Masculino , Pessoa de Meia-Idade , Países Baixos/epidemiologia , Farmacoepidemiologia , Fatores de Risco
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa